top of page

Mwandishi:

Mhariri:

Imeboreshwa:

ULY CLINIC

ULY CLINIC

20 Februari 2026, 04:36:31

Management based on disease severity COVID-19

Management based on disease severity COVID-19
Management based on disease severity COVID-19
Management based on disease severity COVID-19
Management based on disease severity COVID-19

There is no single curative (“magic-bullet”) therapy for COVID-19. The disease is a multi-phase viral-inflammatory syndrome, therefore treatment requires:

  • Stage-specific therapy

  • Organ support

  • Thrombosis prevention

  • Careful monitoring for deterioration


Management differs according to severity:

  1. Mild disease (Home care)

  2. Moderate disease (Pneumonia)

  3. Severe disease (Severe pneumonia)

  4. Critical disease


A. MILD COVID-19 DISEASE (HOME CARE)


Clinical Definition

Symptomatic patient without hypoxia or pneumonia


Goals of Care

  • Prevent progression

  • Reduce transmission

  • Provide symptom relief

  • Educate patient on danger signs


Discharge & Isolation Instructions

Patient must:

  • Self-isolate

  • Wear mask around others

  • Use separate utensils and sleeping area

  • Maintain hydration and nutrition

  • Monitor symptoms daily


Pharmacologic Treatment


Supportive Supplements

Medication

Dose

Duration

Purpose

Vitamin C

500 mg OD

2 weeks

Immune modulation

Zinc sulphate

40 mg OD

2 weeks

Antiviral support

Vitamin D3

1000–5000 IU OD

2 weeks

Immune regulation


Symptomatic Treatment

  • Antipyretics (Paracetamol)

  • Antihistamine (if URTI symptoms)

  • Cough syrup if needed


Conditional Treatments

Only if clinically suspected:

Condition

Treatment

Bacterial infection

Antibiotics per guideline

Malaria positive

Antimalarial regimen

Other infections

Treat accordingly

Antibiotics are NOT routinely indicated

Patient Education — Danger Signs

Return immediately if:

  • Difficulty breathing

  • Chest tightness

  • Persistent fever

  • Confusion

  • Reduced consciousness


Remarks

  • Early supplements may support immune response

  • Community awareness reduces transmission

  • Zinc deficiency associated with increased infection risk


B. MODERATE COVID-19 DISEASE (PNEUMONIA)


Clinical Definition

Pneumonia with SpO₂ ≥ 90% on room air


Goals of Care

  • Prevent deterioration to severe disease

  • Reduce inflammation

  • Treat bacterial superinfection


Treatment Protocol


Supportive Care

Same supplements as mild disease.


Anti-Inflammatory Therapy

Drug

Dose

Duration

Dexamethasone

6 mg PO OD

5 days

OR



Prednisolone

20 mg PO OD

5 days


Antibiotics (If Suspected Superinfection)

Option 1

  • Azithromycin 500 mg OD × 5 daysPLUS

  • Amoxicillin/Clavulanate 625 mg BD × 7 days

Option 2

  • Azithromycin 500 mg OD × 5 daysPLUS

  • Amoxicillin 500 mg TDS × 7 days

Option 3

  • Azithromycin 500 mg OD × 5 daysPLUS

  • Ceftriaxone 1 g OD × 5 days


Monitoring

  • Daily symptom review

  • Oxygen saturation monitoring

  • Educate on danger signs


C. SEVERE COVID-19 DISEASE (SEVERE PNEUMONIA)

Clinical Definition

Pneumonia with hypoxia → risk ofAcute Respiratory Distress Syndrome


Admission Required

Place in oxygen-equipped isolation room


1. Oxygenation Strategy

Method

Flow Rate

Nasal cannula

1–5 L/min

Face mask

6–10 L/min

Non-rebreather

10–15 L/min

CPAP/NIV

If oxygen inadequate

Encourage awake prone positioning


2. Corticosteroids

Drug

Regimen

Methylprednisolone

80 mg stat → 40 mg BD × 7 days

Hydrocortisone

200 mg BD × 7 days

Dexamethasone

8 mg TDS × 7 days


3. Anticoagulation

COVID-19 causes micro-thrombosis and may progress toSepsis

Preferred

  • Enoxaparin 1 mg/kg SC BD

Alternatives

  • Rivaroxaban 10 mg OD

  • Aspirin 75 mg OD

  • Clopidogrel 75 mg OD


4. Antibiotics

  • Azithromycin OR ClarithromycinPLUS

  • Piperacillin-tazobactam OR Ceftriaxone-Sulbactam

(Change based on culture results)


5. Additional Supportive Care

  • Careful IV fluids

  • Proton pump inhibitor

  • Nutrition therapy

  • Chest physiotherapy

  • Psychosocial support


6. Adjunct Therapies

Therapy

Note

Magnesium

Prevent cytokine storm/QTc prolongation

Ivermectin

Not recommended by major guidelines

Vitamins

Continue supplementation


Key Clinical Principle

Main treatment is correction of hypoxia and organ support


D. CRITICAL COVID-19 DISEASE

Includes:

  • Respiratory failure

  • Septic shock

  • Multi-organ dysfunction

May progress toSeptic shock


ICU ADMISSION REQUIRED


i. Airway & Ventilation

  • Intubate if airway not protected

  • Mechanical ventilation:

    • SpO₂ target > 90%

    • Tidal volume 4–8 mL/kg

    • Plateau pressure < 30 cmH₂O


ii. Oxygenation

  • High-flow oxygen → NIV → Mechanical ventilation

  • Awake or ventilated proning


iii. Steroids

Same as severe disease


iv. Anticoagulation

Same protocol as severe disease


v. Hemodynamic Support

  • IV fluids for shock

  • Maintain MAP ≥ 65 mmHg

  • Vasopressors if needed


vi. Antibiotics

Broad spectrum therapy then culture-guided


vii. Organ Support

  • Renal support (dialysis if needed)

  • Nutrition therapy

  • Stress ulcer prophylaxis

  • Physiotherapy


Investigational/Adjunct Therapies

Used in some settings:

  • Remdesivir

  • Tocilizumab

  • Colchicine

(Used selectively depending on protocol and availability)


CORE PRINCIPLE OF COVID-19 MANAGEMENT

Mild → symptomatic careModerate → anti-inflammatory therapySevere → oxygen + steroids + anticoagulationCritical → organ support + ICU care


References

  1. Ministry of Health, Community Development, Gender, Elderly and Children (United Republic of Tanzania). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. March 2021.

  2. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. WHO; 2020.

  3. World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed. WHO Interim Guidance; 2020.

  4. World Health Organization. Coronavirus disease (COVID-19) Situation Report – 46. WHO; 2020.

  5. Del Rio C, Malani PN. 2019 Novel Coronavirus—Important Information for Clinicians. JAMA. 2020;323(11):1039-1040.

  6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-1720.

  7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of COVID-19 pneumonia in Wuhan, China. Lancet. 2020;395(10223):507-513.

  8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China. Lancet. 2020;395:1054-1062.

  9. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020.

  10. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest Radiographic and CT Findings of COVID-19: Analysis of Nine Patients Treated in Korea. Korean J Radiol. 2020;21(4):494-500.

  11. Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of COVID-19 pneumonia. Intensive Care Med. 2020.

  12. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.

  13. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign Guidelines on the Management of Critically Ill Adults with COVID-19. Crit Care Med. 2020.

  14. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.

  15. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012;307(23):2526-2533.

  16. Australian and New Zealand Intensive Care Society (ANZICS). COVID-19 Guidelines. Melbourne; 2020.

  17. World Confederation for Physical Therapy. Physiotherapy management for COVID-19 (Version 1.0). 2020.

  18. Queensland Health Clinical Excellence Division. COVID-19 Action Plan: Statewide General Medicine Clinical Network. 2020.


Imeandikwa:

24 Machi 2021, 14:49:23

bottom of page